Clin2
NCT05733013Possibly a fitRecruiting

Using redifferentiation medicines before radioactive iodine for thyroid cancer

Thyroid CancerThyroidRefractory Thyroid Cancer

Part of Cancer, Hormones & metabolism clinical trials.

This study collects information on how redifferentiation medicines used before radioactive iodine work in everyday care for certain thyroid cancers that are unlikely to respond to radioactive iodine. It may help doctors understand the best real-world way to use these medicines to plan and deliver treatment.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
100 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You must be age 18 or older when you sign consent.
  • You have thyroid cancer that is unlikely to respond to radioactive iodine, or it no longer responds to it.
  • Your care plan will include giving a redifferentiation medicine before you get radioactive iodine for diagnosis and/or treatment.
  • You have not used redifferentiation medicines outside a clinical trial, or—if you have—your team will collect past details and you’ll also share new details after consent.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT04290663Recruiting· Phase 3
Radioiodine decision after thyroid surgery for intermediate-risk cancer

This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.

Pointe à Pitre, Guadeloupe
NCT07056218Not yet recruiting
Radioactive iodine treatment for low-risk thyroid cancer

This study looks at how well radioactive iodine therapy works for patients with certain types of thyroid cancer that are considered low or intermediate risk. It may help you understand if this treatment is right for you.

NCT03841617Recruiting· Phase 2
Measure radiation in thyroid cancer using a special PET-CT scan

This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.

Bethesda, Maryland
NCT06980103Recruiting
Decision aid for RAI in thyroid cancer

This trial offers a decision aid to help you choose whether to have radioactive iodine (RAI) treatment after thyroid cancer surgery. You may qualify if you have intermediate-risk thyroid cancer and haven't yet made a decision about RAI.

Washington D.C., District of Columbia
NCT06558981Recruiting· Phase 3
Radiation therapy after thyroid surgery for high-risk cancer

This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.

Shanghai
NCT06647602Not yet recruiting
Thyroid hormone after radioactive iodine: value and effectiveness

This study looks at how well thyroid hormone replacement works after radioactive iodine treatment for high-risk thyroid cancer. It may help find the best way to manage your hormone levels after treatment.

Groningen, Provincie Groningen

Hear when a new Thyroid Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.